[go: up one dir, main page]

WO2009028588A1 - 多環式化合物 - Google Patents

多環式化合物 Download PDF

Info

Publication number
WO2009028588A1
WO2009028588A1 PCT/JP2008/065365 JP2008065365W WO2009028588A1 WO 2009028588 A1 WO2009028588 A1 WO 2009028588A1 JP 2008065365 W JP2008065365 W JP 2008065365W WO 2009028588 A1 WO2009028588 A1 WO 2009028588A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
polycyclic compound
alkyl group
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065365
Other languages
English (en)
French (fr)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Mamoru Takaishi
Takeo Sasaki
Yu Yoshida
Toshiyuki Uemura
Takashi Doko
Daisuke Shinmyo
Daiju Hasegawa
Takehiko Miyagawa
Hiroaki Hagiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2010002098A priority Critical patent/MX2010002098A/es
Priority to AU2008292390A priority patent/AU2008292390B2/en
Priority to CN200880104785XA priority patent/CN101815713B/zh
Priority to EP08828870.9A priority patent/EP2181992B8/en
Priority to NZ583515A priority patent/NZ583515A/en
Priority to JP2009530168A priority patent/JP5433418B2/ja
Priority to CA2694401A priority patent/CA2694401C/en
Priority to BRPI0815773A priority patent/BRPI0815773A2/pt
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to US12/671,873 priority patent/US9453000B2/en
Priority to UAA201003641A priority patent/UA97855C2/ru
Publication of WO2009028588A1 publication Critical patent/WO2009028588A1/ja
Priority to ZA2010/00474A priority patent/ZA201000474B/en
Priority to IL203778A priority patent/IL203778A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

　式（Ｉ） ［式中、 Ａｒ１は、Ｃ１－６アルキル基で置換されてもよいイミダゾリル基等を示し、 Ａｒ２は、Ｃ１－６アルコキシ基で置換されてもよいフェニル基等を示し、 Ｘ１は、二重結合等を示し、 Ｈｅｔは、Ｃ１－６アルキル基等で置換されてもよいトリアゾリル基等を示す］で表される化合物または薬理学的に許容される塩は、Ａβに起因する疾患の治療剤または予防剤として有効である。
PCT/JP2008/065365 2007-08-31 2008-08-28 多環式化合物 Ceased WO2009028588A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2694401A CA2694401C (en) 2007-08-31 2008-08-28 Polycyclic compound
CN200880104785XA CN101815713B (zh) 2007-08-31 2008-08-28 多环化合物
EP08828870.9A EP2181992B8 (en) 2007-08-31 2008-08-28 Polycyclic compound
NZ583515A NZ583515A (en) 2007-08-31 2008-08-28 Imidazole-pyridine derivative featuring a 1,2,4-triazole ring fused to a 5-7 membered ring, for treating a disease caused by amyloid-beta such as Alzheimer's, dementia, Down's syndrome, and amyloidosis
JP2009530168A JP5433418B2 (ja) 2007-08-31 2008-08-28 多環式化合物
BRPI0815773A BRPI0815773A2 (pt) 2007-08-31 2008-08-28 composto, e, medicamento.
US12/671,873 US9453000B2 (en) 2007-08-31 2008-08-28 Polycyclic compound
MX2010002098A MX2010002098A (es) 2007-08-31 2008-08-28 Compuesto policiclico.
AU2008292390A AU2008292390B2 (en) 2007-08-31 2008-08-28 Polycyclic compound
UAA201003641A UA97855C2 (en) 2007-08-31 2008-08-28 Polycyclic compound
ZA2010/00474A ZA201000474B (en) 2007-08-31 2010-01-21 Polycyclic compound
IL203778A IL203778A (en) 2007-08-31 2010-02-08 History of polycyclic cinnamide, medicinal preparations containing them, and their use in the prevention or treatment of beta-amyloid disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007-225045 2007-08-31
JP2007225045 2007-08-31
JP2008020009 2008-01-31
JP2008-020009 2008-01-31
JP2008-123057 2008-05-09
JP2008123057 2008-05-09

Publications (1)

Publication Number Publication Date
WO2009028588A1 true WO2009028588A1 (ja) 2009-03-05

Family

ID=40387302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065365 Ceased WO2009028588A1 (ja) 2007-08-31 2008-08-28 多環式化合物

Country Status (19)

Country Link
US (1) US9453000B2 (ja)
EP (2) EP2181992B8 (ja)
JP (1) JP5433418B2 (ja)
KR (1) KR20100055456A (ja)
CN (1) CN101815713B (ja)
AR (1) AR068121A1 (ja)
AU (1) AU2008292390B2 (ja)
BR (1) BRPI0815773A2 (ja)
CA (1) CA2694401C (ja)
CL (1) CL2008002542A1 (ja)
ES (1) ES2529648T3 (ja)
IL (1) IL203778A (ja)
MX (1) MX2010002098A (ja)
MY (1) MY150507A (ja)
NZ (1) NZ583515A (ja)
PE (1) PE20090674A1 (ja)
TW (1) TW200916469A (ja)
WO (1) WO2009028588A1 (ja)
ZA (1) ZA201000474B (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025197A1 (en) * 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
WO2010098490A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
WO2010098332A1 (ja) * 2009-02-26 2010-09-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物の製造法およびその中間体
WO2010098496A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Process for producing tetrahydrotriazolopyridine derivative
CN102574776A (zh) * 2009-07-31 2012-07-11 桑多斯股份公司 ω-氨基-烷酰胺和ω-氨基-烷硫酰胺的制备方法及该方法的中间体
US8349880B2 (en) 2009-01-16 2013-01-08 Bristol-Myers Squibb Company Bicyclic compounds for the reduction of beta-amyloid production
JP2013517246A (ja) * 2010-01-15 2013-05-16 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γセクレターゼ調節物質としての新規置換二環トリアゾール誘導体
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
JP2021512946A (ja) * 2018-02-05 2021-05-20 ユニヴェルスィテ・ドゥ・ストラスブール 疼痛を治療するための化合物および組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8129530B2 (en) * 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP5433418B2 (ja) 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
KR20140146216A (ko) 2008-11-19 2014-12-24 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
MX2011011972A (es) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
EP2429522A4 (en) * 2009-05-11 2013-01-09 Univ California METHOD FOR REDUCING THE CONCENTRATION OF UBIQUITINATED PROTEINS
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
HK1208356A1 (en) 2012-05-08 2016-03-04 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10372396B2 (en) * 2013-02-21 2019-08-06 Lenovo ( Singapore) Pte. Ltd. Discovery and connection to wireless displays
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
EP4378463A3 (en) * 2017-06-02 2024-10-23 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
EP3920921A4 (en) 2019-02-07 2022-11-02 Alsatech, Inc. POLYVALENT EMOXYPIN DERIVATIVES
CN120712258A (zh) * 2022-12-15 2025-09-26 西特瑞治疗有限公司 用于治疗或预防炎性疾病或与不良免疫反应相关的疾病的取代吡啶类化合物
CN118459425B (zh) * 2024-04-29 2025-11-14 南通华祥医药科技有限公司 一种吡咯烷-1-胺-二盐酸盐的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2004520292A (ja) * 2000-12-04 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー グルタメート受容体アンタゴニストとしてのフェニルエテニルまたはフェニルエチニル誘導体
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
JP2007523903A (ja) * 2004-02-12 2007-08-23 トランス　テック　ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
WO2007102580A1 (ja) * 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A7 (fi) 1989-05-19 1990-11-20 Eisai Co Ltd Buteenihappojohdannaiset
ES2100943T3 (es) 1990-02-08 1997-07-01 Eisai Co Ltd Derivado de bencenosulfonamida.
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
CZ251896A3 (en) 1995-09-12 1997-04-16 Hoffmann Ka Roche Ag F Cephalosporin derivatives
EP0866705A4 (en) 1995-10-19 1999-03-03 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
ES2175404T3 (es) 1996-05-10 2002-11-16 Icos Corp Derivados de carbolina.
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
AU6520098A (en) 1997-03-31 1998-10-22 Takeda Chemical Industries Ltd. Azole compounds, their production and their use
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
SK141799A3 (en) 1997-04-16 2000-08-14 Abbott Lab 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
NZ505515A (en) 1997-12-31 2003-03-28 Univ Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6048678A (en) * 1998-12-28 2000-04-11 Eastman Kodak Company Protective overcoat coating compositions
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
WO2000051981A1 (en) 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
WO2001068585A1 (en) 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
CA2405170A1 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003022273A1 (en) 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
DE60220424T2 (de) 2001-09-14 2008-03-06 Novo Nordisk A/S NEUE LIGANDEN FÜR DIE HisB10 Zn2+ STELLEN DES INSULIN-HEXAMERS IN DER R-KONFORMATION
IL161940A0 (en) 2001-11-22 2005-11-20 Ono Pharmaceutical Co Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
US7582657B2 (en) 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2003074497A1 (en) 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
PT2527315E (pt) 2002-05-31 2014-06-24 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
US7459476B2 (en) 2002-06-27 2008-12-02 Elan Pharmaceuticals, Inc. Methods for treating Alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
HRP20050022A2 (en) 2002-07-12 2006-03-31 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
CN1795165A (zh) 2003-04-01 2006-06-28 普拉斯化学品有限公司 无定形辛伐他汀钙及其制备方法
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
GEP20084571B (en) 2003-12-22 2008-12-25 Pfizer Triazole derivatives as vasopressin antagonists
NZ549449A (en) 2004-03-09 2009-05-31 Merck & Co Inc HIV Integrase inhibitors
WO2006018662A2 (en) 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
DE602005019602D1 (de) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
JPWO2007058304A1 (ja) 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
EP1950211A4 (en) 2005-11-18 2011-08-31 Eisai R&D Man Co Ltd PROCESS FOR PREPARING A CINEMA ACID AMID DERIVATIVE
AU2006317457B2 (en) 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
CN101809019A (zh) 2007-05-07 2010-08-18 先灵公司 γ分泌酶调节剂
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
JP2010535762A (ja) 2007-08-06 2010-11-25 シェーリング コーポレイション ガンマセクレターゼモジュレーター
JP5433418B2 (ja) 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
WO2009126311A1 (en) * 2008-04-11 2009-10-15 The University Of Texas, M.D. Anderson Cancer Center Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
WO2010025197A1 (en) 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
US8703954B2 (en) 2009-02-26 2014-04-22 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
RS52801B (sr) 2009-02-26 2013-10-31 Boehringer Ingelheim International Gmbh Jedinjenja kao antagonisti bradikinina-b1
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
SG173768A1 (en) 2009-02-26 2011-09-29 Glaxo Group Ltd Pyrazole derivatives used as ccr4 receptor antagonists
CN102333628A (zh) 2009-02-27 2012-01-25 Hoya株式会社 模具和用于制造塑料透镜的方法
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
US8381014B2 (en) * 2010-05-06 2013-02-19 International Business Machines Corporation Node controller first failure error management for a distributed system

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2004520292A (ja) * 2000-12-04 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー グルタメート受容体アンタゴニストとしてのフェニルエテニルまたはフェニルエチニル誘導体
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
JP2007504282A (ja) * 2003-05-14 2007-03-01 トリーパインズ セラピューティクス， インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
JP2007523903A (ja) * 2004-02-12 2007-08-23 トランス　テック　ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2007102580A1 (ja) * 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEST JD: "In vivo characterization of A? (40) changes in brain and cerebrospinal fluid using the novel y-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulphonlamide (MK-560) in the rat", THE JOURNAL OF PHARMACOLOGY AND EXPERIMANTAL THERAPEUTICS, vol. 7, no. 2, 31 May 2006 (2006-05-31), pages 786 - 790
BEST JD: "The novel y-secretase inhibitor N-[cis-4-[(4-chlorophenvl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl)-1, 1, 1-trifluoromethanesulphonlamide (MK-560) reduces amylid plaque deposition without evidence notch-related pathology in the Tg2576 mouse", THE JOURNAL OF PHARMACOLOGY AND EXPERIMANTAL THERAPEUTICS, vol. 20, no. 2, 3 February 2007 (2007-02-03), pages 552 - 558
See also references of EP2181992A4 *
SIEMERS ER: "Effects of a y-secretase inhibitor in a randamized study of patients with Alzheimer disease", NEUROLOGY, vol. 66, 2006, pages 602 - 604

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025197A1 (en) * 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
US8349880B2 (en) 2009-01-16 2013-01-08 Bristol-Myers Squibb Company Bicyclic compounds for the reduction of beta-amyloid production
US8703954B2 (en) 2009-02-26 2014-04-22 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
CN102333778B (zh) * 2009-02-26 2015-05-13 卫材R&D管理有限公司 四氢三唑并吡啶衍生物的盐及其晶体
CN102333778A (zh) * 2009-02-26 2012-01-25 卫材R&D管理有限公司 四氢三唑并吡啶衍生物的盐及其晶体
WO2010098496A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Process for producing tetrahydrotriazolopyridine derivative
WO2010098332A1 (ja) * 2009-02-26 2010-09-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物の製造法およびその中間体
WO2010098490A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
CN102574776A (zh) * 2009-07-31 2012-07-11 桑多斯股份公司 ω-氨基-烷酰胺和ω-氨基-烷硫酰胺的制备方法及该方法的中间体
JP2013517246A (ja) * 2010-01-15 2013-05-16 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γセクレターゼ調節物質としての新規置換二環トリアゾール誘導体
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
JP2021512946A (ja) * 2018-02-05 2021-05-20 ユニヴェルスィテ・ドゥ・ストラスブール 疼痛を治療するための化合物および組成物
JP7506379B2 (ja) 2018-02-05 2024-06-26 ユニヴェルスィテ・ドゥ・ストラスブール 疼痛を治療するための化合物および組成物

Also Published As

Publication number Publication date
AU2008292390A1 (en) 2009-03-05
TW200916469A (en) 2009-04-16
US20110009619A1 (en) 2011-01-13
JP5433418B2 (ja) 2014-03-05
US9453000B2 (en) 2016-09-27
EP2181992B8 (en) 2013-06-26
AU2008292390B2 (en) 2013-04-04
ZA201000474B (en) 2011-05-25
CA2694401C (en) 2012-12-04
CA2694401A1 (en) 2009-03-05
KR20100055456A (ko) 2010-05-26
BRPI0815773A2 (pt) 2019-09-24
CN101815713A (zh) 2010-08-25
PE20090674A1 (es) 2009-06-19
EP2181992A1 (en) 2010-05-05
EP2559693A1 (en) 2013-02-20
EP2559693B1 (en) 2014-11-26
JPWO2009028588A1 (ja) 2010-12-02
NZ583515A (en) 2011-05-27
AR068121A1 (es) 2009-11-04
IL203778A (en) 2013-11-28
CN101815713B (zh) 2013-09-11
MY150507A (en) 2014-01-30
EP2181992B1 (en) 2013-05-01
MX2010002098A (es) 2010-03-30
ES2529648T3 (es) 2015-02-24
CL2008002542A1 (es) 2009-01-02
EP2181992A4 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
WO2009028588A1 (ja) 多環式化合物
TNSN08343A1 (en) Polycyclic cinnamide derivative
EA200870336A1 (ru) Полициклические производные циннамида
WO2007112093A3 (en) Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
PL2090570T3 (pl) Pochodna imidazolu
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2011110583A3 (en) Fungicidal mixtures comprising triazole derivatives
WO2011004162A3 (en) 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2010056644A8 (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
AU2010243044A8 (en) Carbinol compound having heterocyclic linker
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
WO2008019030A3 (en) Modified azole compounds as antiinfective agents
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
MX2009012349A (es) Compuestos de ((fenil)imidazolil)metilheteroarilo.
UA97855C2 (en) Polycyclic compound
CY1112554T1 (el) Παραγωγο 4-(3-βενζοϋλαμινοφαινυλ)-6,7-διμεθοξυ-2-μεθυλαμινοκιναζολινης
UA95472C2 (en) Polycyclic cinnamide derivatives
WO2014005134A3 (en) 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof
NO20084180L (no) Polycykliske cinnamidderivater
WO2009078036A3 (en) Process and intermediate of letrozole
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880104785.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828870

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009530168

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12010500161

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2694401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008292390

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 807/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 203778

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008828870

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 583515

Country of ref document: NZ

Ref document number: MX/A/2010/002098

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008292390

Country of ref document: AU

Date of ref document: 20080828

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010000422

Country of ref document: MY

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107005314

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201003641

Country of ref document: UA

Ref document number: 2010112383

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12671873

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0815773

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100223